Cellspan Esophageal Implants may offer improved outcomes for patients by potentially simplifying surgical techniques to reduce post-operative complications, improve quality of life and enable regeneration of the patient’s own esophagus.
Cellspan implants are intended to offer numerous advantages over standard surgical resection:
- Eliminate use of the stomach or intestine to create a mock esophagus
- Reduce complications and improve post-surgical morbidity
- Use in patients who are not fit for surgery
- Reduce costs through reduced hospitalization and morbidity rates
With about 16,910 new esophageal cancer cases estimated in 2016 in the U.S., Cellspan implants have the potential to improve outcomes and change treatment paradigms.
Biostage intends to submit the Cellspan Esophageal Implant IND with the FDA in the third quarter of 2017 and begin first-in-man studies in the fourth quarter of 2017.
Cellspan Esophageal Implants for Pediatric Esophageal Atresia
Biostage is developing its Cellspan esophageal implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. In most cases, the upper esophagus does not connect with the lower esophagus and stomach. Esophageal atresia occurs in about 1 in every 4,000 live births worldwide.